Michael A. Metzger, serving as both Chief Executive Officer and a director at Syndax Pharmaceuticals Inc (NASDAQ:SNDX), completed the sale of 32,375 shares of the company's common stock on July 8, 2026. The aggregate value of these transactions reached $784,776, with the shares being sold at prices fluctuating between $24.00 and $24.43. This executive divestment takes place as the stock trades near its 52-week high of $25.59, a period marked by a remarkable 166% return over the past year, according to InvestingPro data. The stock currently trades at $24.84, with the company holding a market capitalization of $2.19 billion.
Before executing the sale, Mr. Metzger acquired 32,375 shares of common stock by exercising stock options at a price of $6.38 per share, representing a total value of $206,552. These options were fully vested. The sale of common stock was executed pursuant to a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for selling shares to avoid accusations of insider trading.
Following these transactions, Mr. Metzger directly holds 484,843 shares of Syndax Pharmaceuticals common stock. He also retains 1,564,551 vested and immediately exercisable options to purchase common stock, and an additional 813,949 options that have not yet vested. For deeper insights into SNDX's valuation and performance, InvestingPro offers access to 12 additional ProTips and comprehensive Pro Research Reports covering over 1,400 US equities.
In other recent news, Syndax Pharmaceuticals announced the pricing of $250 million in convertible senior notes due 2031, with a 2.25% interest rate. This transaction, facilitated by J. Wood Capital Advisors LLC, is expected to close soon, pending customary conditions. Additionally, Syndax presented significant data from its Phase 1/2 SAVE trial at the European Hematology Association Congress. The trial involved an oral combination therapy for relapsed or refractory acute myeloid leukemia, showing promising results in patients with specific genetic mutations.
Furthermore, the company shared results from 12 abstracts focused on revumenib, revealing an 82% overall response rate in a real-world study. Analysts from Stifel and H.C. Wainwright reiterated their Buy ratings for Syndax, citing positive data from the European Hematology Association meeting. Stifel set a price target of $46.00, while H.C. Wainwright set it at $40.00. These developments highlight the ongoing progress in Syndax's leukemia treatment research and financial strategies.